Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

Eiji Oki,Yasunori Emi,Yuji Miyamoto,Akira Kabashima,Hidefumi Higashi,Yutaka Ogata,Masahiko Ikebe,Hiroshi Saeki,Shoji Tokunaga,Ken Shirabe,Toru Beppu,Shinji Uchida,Mitsuhisa Takatsuki,Masahiko Sakoda,Susumu Eguchi,Yoshito Akagi,Yoshihiro Kakeji,Hideo Baba,Shoji Natsugoe,Yoshihiko Maehara

Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

2015

Background The Kyushu Study Group of Clinical Cancer (KSCC) conducted phase II trials of KSCC1002 (UMIN000001308) concerning liver resectability after first-line treatment of initially unresectable or not optimally resectable colorectal liver metastases in a prospective, multicenter study.

Keywords:

Capecitabine
Cetuximab
Cancer
Bevacizumab
Colorectal cancer
General surgery
Survival rate
Tegafur
Oxaliplatin
Medicine
Internal medicine
Oncology
multicenter study
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations